Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Diagnostics COVID-19, Microbiology and immunology

Staying One Step Ahead of Viral Infection

Even before COVID-19 took over the world, researchers from Duke Health were investigating biomarkers to identify presymptomatic respiratory viruses and help control their spread (1) – a focus they did not realize would become so crucial so quickly. After all, acute viral infections are the most common reason for primary care visits in high-income countries. And, after COVID-19, viral outbreaks will continue to threaten public health worldwide. Despite this need, we face logistical barriers to detecting infection early, such as availability of tools and the need for a priori knowledge of the pathogen in question.

Over five years, the Duke Health team recruited and monitored 1,465 students for symptoms of respiratory infection. 264 index cases were identified, with RT-PCR confirming presence of viral infection in 57 percent of cases and detecting nine different viruses in total. Close contacts of confirmed cases were monitored for symptoms and viral shedding; a blood-based 36-gene RT-PCR assay measured transcriptomic responses.

The assay accurately predicted infection up to three days before peak illness, when symptoms were minimal or absent and before viral shedding was detectable. The assay was 99 percent accurate for predicting illness from influenza, 95 percent accurate for adenovirus, and 93 percent accurate for the cold-causing coronavirus strain.

“We can use the body’s natural immune response signals to detect a viral infection with a high degree of accuracy, even at a time when people have been exposed to the pathogen but don’t yet feel sick,” said Micah McClain, lead author of the study (2).

Transcriptional biomarkers could be used to inform outbreak management across a range of viral causes and stages of disease. Now, the team is looking at the effectiveness of these markers in detecting SARS-CoV-2. “Our data show that these biomarkers of viral infection are present and detectable before clinical disease develops and thus could form the basis of novel approaches to early identification and management of emerging viral outbreaks and pandemics,” said McClain.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. MT McClain et al., Lancet Infect Dis, [Online ahead of print] (2020). PMID: 32979932.
  2. Duke Health (2020). Available at: bit.ly/3iZPlSt.
About the Author
Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register